MB
CRVS icon

MPM BioImpact’s Corvus Pharmaceuticals CRVS Stock Holding History

MPM BioImpact’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,674,875
Closed -$24.5M – 41
2026
Q1 		$24.5M Sell
1,674,875
-1,068,796
-39% -$17.1M 1.89% 23
2025
Q4 		$21.1M Buy
+2,743,671
New +$21.6M 2.42% 19

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MPM BioImpact's CRVS Position: Q2 2026 in Review

MPM BioImpact sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 1,674,875 shares — an estimated $24.5M sold.

MPM BioImpact first reported a position in CRVS in Q4 2025 and held it in 2 quarters. The position peaked at $24.5M in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • MPM BioImpact reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MPM BioImpact sold 1,674,875 Corvus Pharmaceuticals shares in Q2 2026, an estimated $24.5M.
  • MPM BioImpact first reported a position in Corvus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • MPM BioImpact's Corvus Pharmaceuticals position peaked at $24.5M in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.